|
rdf:type |
|
|
lifeskim:mentions |
|
|
pubmed:issue |
8
|
|
pubmed:dateCreated |
2011-8-26
|
|
pubmed:abstractText |
Imatinib-resistant tyrosine kinase (TK) fusions involving FGFR1, JAK2, or FLT3 are rare but recurrent in patients with eosinophilia-associated neoplasms. We report here 2 male patients with ETV6-FLT3(+) myeloid/lymphoid neoplasms with eosinophilia who were treated with the multitargeted TK inhibitors sunitinib and sorafenib. Patient 1 achieved rapid complete hematologic response and complete cytogenetic response after 3 months of taking sunitinib. A secondary blast phase caused by clonal evolution was diagnosed after 6 months. He achieved a second complete hematologic response after taking sorafenib but relapsed 2 months later. An N841K point mutation within the TK domain of FLT3, previously reported in acute myeloid leukemia and potentially conferring resistance to sorafenib, was subsequently identified. Patient 2 was heavily pretreated according to the initial diagnosis of T-lymphoblastic lymphoma and died in sunitinib-induced pancytopenia. This report highlights the importance of a careful diagnostic workup for eosinophilia-associated neoplasms to evaluate the possibility of TK inhibitor therapy.
|
|
pubmed:language |
eng
|
|
pubmed:journal |
|
|
pubmed:citationSubset |
AIM
|
|
pubmed:chemical |
http://linkedlifedata.com/resource/pubmed/chemical/Antineoplastic Agents,
http://linkedlifedata.com/resource/pubmed/chemical/Benzenesulfonates,
http://linkedlifedata.com/resource/pubmed/chemical/DNA, Neoplasm,
http://linkedlifedata.com/resource/pubmed/chemical/ETS translocation variant 6 protein,
http://linkedlifedata.com/resource/pubmed/chemical/FLT3 protein, human,
http://linkedlifedata.com/resource/pubmed/chemical/Indoles,
http://linkedlifedata.com/resource/pubmed/chemical/Oncogene Proteins, Fusion,
http://linkedlifedata.com/resource/pubmed/chemical/Protein Kinase Inhibitors,
http://linkedlifedata.com/resource/pubmed/chemical/Proto-Oncogene Proteins c-ets,
http://linkedlifedata.com/resource/pubmed/chemical/Pyridines,
http://linkedlifedata.com/resource/pubmed/chemical/Pyrroles,
http://linkedlifedata.com/resource/pubmed/chemical/Repressor Proteins,
http://linkedlifedata.com/resource/pubmed/chemical/fms-Like Tyrosine Kinase 3,
http://linkedlifedata.com/resource/pubmed/chemical/sorafenib,
http://linkedlifedata.com/resource/pubmed/chemical/sunitinib
|
|
pubmed:status |
MEDLINE
|
|
pubmed:month |
Aug
|
|
pubmed:issn |
1528-0020
|
|
pubmed:author |
pubmed-author:BloorAdrianA,
pubmed-author:CrossNicholas C PNC,
pubmed-author:ErbenPhilippP,
pubmed-author:GeskStefanS,
pubmed-author:HaferlachClaudiaC,
pubmed-author:HaferlachTorstenT,
pubmed-author:HochhausAndreasA,
pubmed-author:HofmannWolf-KarstenWK,
pubmed-author:MetzgerothGeorgiaG,
pubmed-author:ReiterAndreasA,
pubmed-author:RitterMichaelM,
pubmed-author:ScoreJoannahJ,
pubmed-author:TelfordNickN,
pubmed-author:WalzChristophC
|
|
pubmed:issnType |
Electronic
|
|
pubmed:day |
25
|
|
pubmed:volume |
118
|
|
pubmed:owner |
NLM
|
|
pubmed:authorsComplete |
Y
|
|
pubmed:pagination |
2239-42
|
|
pubmed:meshHeading |
pubmed-meshheading:21705501-Adult,
pubmed-meshheading:21705501-Amino Acid Sequence,
pubmed-meshheading:21705501-Antineoplastic Agents,
pubmed-meshheading:21705501-Base Sequence,
pubmed-meshheading:21705501-Benzenesulfonates,
pubmed-meshheading:21705501-DNA, Neoplasm,
pubmed-meshheading:21705501-Drug Resistance, Neoplasm,
pubmed-meshheading:21705501-Eosinophilia,
pubmed-meshheading:21705501-Hematologic Neoplasms,
pubmed-meshheading:21705501-Humans,
pubmed-meshheading:21705501-Indoles,
pubmed-meshheading:21705501-Male,
pubmed-meshheading:21705501-Middle Aged,
pubmed-meshheading:21705501-Molecular Sequence Data,
pubmed-meshheading:21705501-Oncogene Fusion,
pubmed-meshheading:21705501-Oncogene Proteins, Fusion,
pubmed-meshheading:21705501-Point Mutation,
pubmed-meshheading:21705501-Protein Kinase Inhibitors,
pubmed-meshheading:21705501-Proto-Oncogene Proteins c-ets,
pubmed-meshheading:21705501-Pyridines,
pubmed-meshheading:21705501-Pyrroles,
pubmed-meshheading:21705501-Repressor Proteins,
pubmed-meshheading:21705501-fms-Like Tyrosine Kinase 3
|
|
pubmed:year |
2011
|
|
pubmed:articleTitle |
Response of ETV6-FLT3-positive myeloid/lymphoid neoplasm with eosinophilia to inhibitors of FMS-like tyrosine kinase 3.
|
|
pubmed:affiliation |
Pathologisches Institut, Ludwig-Maximilians-Universität, München, Germany.
|
|
pubmed:publicationType |
Journal Article,
Case Reports,
Research Support, Non-U.S. Gov't
|
